Trials / Completed
CompletedNCT05701007
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
Real World Evidence Study on Metastatic Prostate Cancer Patient Characteristics, Treatment Patterns and Outcomes in the Pirkanmaa Hospital District in Finland
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,083 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Comprehensive understanding of the epidemiology and disease burden of metastatic prostate cancer patients in Finland is lacking. This study will address the following questions: * What are the demographic and clinical characteristics of metastatic prostate cancer patients? * How are metastatic prostate cancer patients currently treated and how effective are these treatments? * How does the development of castration-resistance affect patient outcomes? * What is the economic burden of metastatic prostate cancer?
Conditions
- Metastatic Castration Sensitive Prostate Cancer (mCSPC)
- Metastatic Castration Resistant Prostate Cancer (mCRPC)
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | abiraterone | mCRPC |
| DRUG | enzalutamide | mCRPC |
| DRUG | docetaxel | mCRPC |
| DRUG | apalutamide | mCRPC |
| DRUG | cabazitaxel | mCRPC |
| DRUG | Radium-223 | mCRPC |
| DRUG | Lutetium-177 | mCRPC |
| DRUG | degarelix | mCSPC |
| DRUG | goserelin | mCSPC |
| DRUG | leuprorelin | mCSPC |
| DRUG | triptorelin | mCSPC |
Timeline
- Start date
- 2023-02-13
- Primary completion
- 2024-04-10
- Completion
- 2024-04-10
- First posted
- 2023-01-26
- Last updated
- 2026-01-29
- Results posted
- 2026-01-29
Locations
1 site across 1 country: Finland
Source: ClinicalTrials.gov record NCT05701007. Inclusion in this directory is not an endorsement.